Compare Samsara Inc (IOT) vs Mesoblast Limited (MESO) Price & Performance

Samsara Inc. (IOT) trades at $40.51, down 2.95% on the day, but maintains a bullish technical outlook with strong analyst support. The company reported robust Q2 2027 results, beating earnings estimates with $0.20 EPS versus $0.16 expected, and achieved 30% year-over-year revenue growth. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion.

The stock offers upside to the $51.15 consensus price target, driven by solid fundamentals and institutional accumulation. However, elevated valuation multiples (P/E 270.07, P/S 12.79) and negative net income in 2025 pose risks if growth moderates. Positive cash flow trends and a 75% buy rating from analysts support a constructive outlook, though investors should monitor competitive pressures and execution on profitability goals.

MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.

The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.